UA-2012 (and related non-myristoylated analog UA-1907) is a lead alpha-helical cyclic peptide which inhibits the focal adhesion kinase (FAK)-paxillin protein-protein interaction (PPI) and is being evaluated for the treatment of cutaneous melanoma. Here, PTK2 is linked to cutaneous melanoma.